Table 1.
Patient characteristics at diagnosis (N = 80)
| Median age, years (range) | 63 (40–70) |
|---|---|
| Gender, M/F (N (%)) | 42/38 (53/47) |
| Paraprotein isotype (N (%)) | |
| IgG | 51 (64) |
| IgA | 16 (20) |
| Light chain | 13 (16) |
| Hemoglobin (g/L, median (range)) | 104 (64–141) |
| P-Creatinine (μmol/L, median (range)) | 80 (47–404) |
| S-β2-Microglobulin (mg/L, median (range)) | 3.1 (1.2–16.6) |
| Bone marrow plasma cells (% (range)) | 46 (10–100) |
| ISS (N (%)) | |
| I | 21 (26) |
| II | 44 (55) |
| III | 15 (19) |
| R-ISS (N (%)) | |
| I | 15 (19) |
| II | 57 (71) |
| III | 8 (10) |
| IMWG risk | |
| Low risk | 10 (13) |
| Standard risk | 59 (74) |
| High risk | 11 (14) |
| FISH findings (N (%)) | |
| Del13q/-13 | 29 (36) |
| Del17p* | 7 (9) |
| +1q | 18 (23) |
| t(4;14) | 7 (9) |
| t(11;14) | 8 (10) |
| t(14;16) | 2 (3) |
| t(6;14) | 1(1) |
| Hyperdiploidy | 15 (19) |
| Other^ | 36 (45) |
| None | 10 (13) |
FISH, fluorescent in situ hybridization; IMWG risk, International Myeloma Working Group Risk Stratification; ISS, International Staging System; R-ISS, Revised International Staging System
*Del17p proportion, median 85% (11–94%), one patient had 11% and all the others > 60%
^del1p32/1p36, del2, -6, del6q, del10, del14q, -12, -16, del16q, t8;14, add14q32, 14q translocations